Regulation of Molecular Diagnostics

Area of Science:

• Regulatory science
• Molecular diagnostics
• Health data governance

Background:

• Molecular diagnostic tests offer rapid genomic and proteomic analysis.
• Existing regulatory frameworks in the US and EU present challenges for these tests.
• Keeping regulations current with technological advancements is a shared difficulty.

Purpose of the Study:

• To compare and contrast US and EU regulatory approaches for molecular diagnostic tests.
• To highlight differences in premarket and postmarket surveillance.
• To examine distinct regulations for laboratory-developed tests (LDTs) and health institution in-house-produced tests.

Main Methods:

• Comparative analysis of US and EU regulatory guidelines.
• Examination of legal frameworks for medical devices and health data protection.
• Review of specific requirements for test samples and data utilization.

Main Results:

• Significant divergence exists in US and EU regulations for molecular diagnostics.
• The US and EU employ markedly different approaches to regulating LDTs and in-house tests.
• Conflicting data protection rules complicate cross-jurisdictional sample and data transfer.

Conclusions:

• Harmonization of regulatory requirements is needed to facilitate global access to molecular diagnostics.
• Addressing data privacy discrepancies is crucial for international research and clinical use.
• Future regulatory strategies must balance innovation with patient safety and data security.